Virosome Biologicals

Virosome Biologicals is a biotechnology company specializing in the development of vaccine delivery platforms using proprietary adjuvanted virosome technology. The company's platform utilizes reconstituted viral envelopes to enhance both humoral and cellular immune responses, with a particular emphasis on mucosal and intranasal administration. Its lead programs have included an intranasal influenza vaccine developed in partnership with Solvay Pharmaceuticals and a respiratory syncytial virus (RSV) candidate. Originally a subsidiary of Norwood Immunology, the company was acquired by Mymetics Corporation in 2009 and subsequently renamed Mymetics BV. Today, its technology serves as a core component of Mymetics' broader vaccine pipeline targeting infectious diseases.